Advertisement

Prostate Cancer

  • Charles D. ScalesJr.
  • Judd W. Moul
Chapter
Part of the Springer Specialist Surgery Series book series (SPECIALIST)

Abstract

Prostate cancer is the most common cancer among men in the United States. In 2010, an estimated 217,730 men will be diagnosed with the disease, and 32,050 will die from prostate cancer.1 Despite a lack of consensus regarding optimal diagnosis and management strategies for prostate cancer, recent data suggest that prostate cancer mortality is decreasing, from 38.6 per 100,000 in 1990 to 25.5 per 100,000 in 2004.1 The current chapter provides an overview of the epidemiology of prostate cancer, current strategies for screening and diagnosis, and treatments for both localized and advanced disease.

Keywords

Prostate Cancer Radical Prostatectomy Zoledronic Acid External Beam Radiation Therapy Prostate Biopsy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Jemal A, Siegel R, Xu J, and Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277PubMedCrossRefGoogle Scholar
  2. 2.
    Ries L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2004. Bethesda, MD: National Cancer Institute; 2007Google Scholar
  3. 3.
    Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality Part II: individual countries. BJU Int. 2002;90:174PubMedCrossRefGoogle Scholar
  4. 4.
    Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality Part I: international comparisons. BJU Int. 2002;90:162PubMedCrossRefGoogle Scholar
  5. 5.
    Bratt O. Hereditary prostate cancer: clinical aspects. J Urol. 2002;168:906PubMedCrossRefGoogle Scholar
  6. 6.
    Bratt O, Damber JE, Emanuelsson M, et al. Hereditary prostate cancer: clinical characteristics and survival. J Urol. 2002;167:2423PubMedCrossRefGoogle Scholar
  7. 7.
    Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008;358:910PubMedCrossRefGoogle Scholar
  8. 8.
    Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215PubMedCrossRefGoogle Scholar
  9. 9.
    Lippman SM, Klein EA, Goodman PJ. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial (SELECT). JAMA. 2009;30(1):39-51CrossRefGoogle Scholar
  10. 10.
    Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005;294:66PubMedCrossRefGoogle Scholar
  11. 11.
    Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350:2239PubMedCrossRefGoogle Scholar
  12. 12.
    Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981PubMedGoogle Scholar
  13. 13.
    Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer. J Natl Cancer Inst. 2003;95:868PubMedCrossRefGoogle Scholar
  14. 14.
    de Koning HJ, Auvinen A, Berenguer Sanchez A, et al. Large-scale randomized prostate cancer screening trials: program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. Int J Cancer. 2002;97:237PubMedCrossRefGoogle Scholar
  15. 15.
    de Koning HJ, Liem MK, Baan CA, et al. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer. 2002;98:268PubMedCrossRefGoogle Scholar
  16. 16.
    Gohagan JK, Prorok PC, Hayes RB, et al. The prostate, lung, colorectal and ovarian (PLCO) cancer screening trial of the National Cancer Institute: history, organization, and status. Control Clin Trials. 2000;21:251SPubMedCrossRefGoogle Scholar
  17. 17.
    Prostate cancer early detection. Practice guidelines in oncology. NCC Network. 2007. Published online by NCCN. http://www.nccn.org/professionals/physician_gls/PDF/prostate_detection.pdf
  18. 18.
    Andriole GL, Grubb RL III, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310PubMedCrossRefGoogle Scholar
  19. 19.
    Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320PubMedCrossRefGoogle Scholar
  20. 20.
    Lu-Yao G, Stukel TA, Yao SL. Prostate-specific antigen screening in elderly men. J Natl Cancer Inst. 2003;95:1792PubMedGoogle Scholar
  21. 21.
    Scales CD Jr, Curtis LH, Norris RD, et al. Prostate specific antigen testing in men older than 75 years in the United States. J Urol. 2006;176:511PubMedCrossRefGoogle Scholar
  22. 22.
    Walter LC, Bertenthal D, Lindquist K, et al. PSA screening among elderly men with limited life expectancies. JAMA. 2006;296:2336PubMedCrossRefGoogle Scholar
  23. 23.
    Deras IL, Aubin SM, Blase A, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008;179:1587PubMedCrossRefGoogle Scholar
  24. 24.
    Sokoll LJ, Ellis W, Lange P, et al. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta. 2008;389:1PubMedCrossRefGoogle Scholar
  25. 25.
    American Joint Committee on Cancer (AJCC). AJCC Cancer Staging Manual. 6th ed. Chicago, IL: American Joint Committee on Cancer; 2002Google Scholar
  26. 26.
    Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110PubMedGoogle Scholar
  27. 27.
    Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277:1445PubMedCrossRefGoogle Scholar
  28. 28.
    Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology. 2001;58:843PubMedCrossRefGoogle Scholar
  29. 29.
    D’Amico AV, Moul J, Carroll PR, et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003;21:2163PubMedCrossRefGoogle Scholar
  30. 30.
    D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969PubMedCrossRefGoogle Scholar
  31. 31.
    Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999;17:1499PubMedGoogle Scholar
  32. 32.
    Albertsen PA, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095-2101PubMedCrossRefGoogle Scholar
  33. 33.
    D’Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125PubMedCrossRefGoogle Scholar
  34. 34.
    D’Amico AV, Renshaw AA, Sussman B, et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294:440PubMedCrossRefGoogle Scholar
  35. 35.
    Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106PubMedCrossRefGoogle Scholar
  36. 36.
    Burnett AL, Aus G, Canby-Hagino ED, et al. Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol. 2007;178:597PubMedCrossRefGoogle Scholar
  37. 37.
    Hu JC, Wang Q, Pashos CL, et al. Utilization and outcomes of minimally invasive radical prostatectomy. J Clin Oncol. 2008;26:2278PubMedCrossRefGoogle Scholar
  38. 38.
    Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233PubMedCrossRefGoogle Scholar
  39. 39.
    Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American urological association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177:540PubMedCrossRefGoogle Scholar
  40. 40.
    Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433PubMedCrossRefGoogle Scholar
  41. 41.
    Moul JW, Wu H, Sun L, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2008;179:S53PubMedCrossRefGoogle Scholar
  42. 42.
    Moul JW, Wu H, Sun L, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004;171:1141PubMedCrossRefGoogle Scholar
  43. 43.
    Freedland SJ, Humphreys EB, Mangold LA, et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol. 2007;25:1765PubMedCrossRefGoogle Scholar
  44. 44.
    Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007;25:1596PubMedCrossRefGoogle Scholar
  45. 45.
    Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512PubMedCrossRefGoogle Scholar

Copyright information

© Springer London 2011

Authors and Affiliations

  • Charles D. ScalesJr.
    • 1
  • Judd W. Moul
    • 2
  1. 1.Division of Urology, Department of SurgeryDuke University Medical CenterDurhamUSA
  2. 2.Department of SurgeryDuke University Medical CenterDurhamUSA

Personalised recommendations